ĐẶC ĐIỂM LÂM SÀNG VÀ CẬN LÂM SÀNG CỦA BỆNH NHÂN UNG THƯ BIỂU MÔ TUYẾN VÚ GIAI ĐOẠN III ĐƯỢC ĐIỀU TRỊ HÓA CHẤT TÂN BỔ TRỢ VÀ PHẪU THUẬT TẠI BỆNH VIỆN K
Main Article Content
Abstract
Objective: To evaluate the clinical and paraclinical characteristics of stage III breast cancer patients treated with neoadjuvant chemotherapy combined with surgery.
Subjects and Methods: This cross-sectional descriptive study with longitudinal follow-up included 250 stage III breast cancer patients treated with neoadjuvant chemotherapy and surgery at the Breast Surgery Department, K Hospital (Tan Trieu campus), from August 2021 to October 2022.
Results: The average age of the patients was 50.14 ± 11.60 years. The majority of patients self-detected the tumor (87.60%), with the most common location being the upper outer quadrant (54.00%) and an average tumor size of 51.80 ± 25.84 mm. The tumors were typically hard (91.09%) and poorly mobile (62.75%). Axillary lymph nodes were involved in 92.8% of patients. Ultrasound findings revealed that 85.20% of patients had a single tumor, with a size primarily between 2-5 cm, and 56.40% were classified as BIRADS 5. Histopathological analysis showed that 82.40% of the cases were invasive carcinoma of no special type, with 44.80% being histological grade II.
Conclusion: Stage III breast cancer patients at K Hospital often self-detect the disease through the presence of a hard and poorly mobile mass, typically located in the upper outer quadrant of the breast. Ultrasound and histopathological findings are crucial for assessing and guiding effective treatment for these patients.
Article Details
Keywords
Stage III breast cancer, Neoadjuvant chemotherapy, Surgery, Clinical characteristics, Paraclinical characteristics
References
2. Krug D, Baumann R, Budach W, et al. Neoadjuvant chemotherapy for breast cancer-background for the indication of locoregional treatment. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft. 2018; 194(9):797-805.
3. Le DT, Bui LT, Nguyen CV, et al. Neoadjuvant doxorubicin-paclitaxel combined chemotherapy in patients with inoperable stage iii breast cancer: A retrospective cohort study with 10 years of follow-up in Vietnam. Oncology and Therapy. 2023; 11(3):327-41.
4. Gnant M, Thomssen C, Harbeck N. St. Gallen/Vienna 2015: A brief summary of the consensus discussion. Breast Care. 2015; 10(2):124-30.
5. Aebi S, Karlsson P, Wapnir IL. Locally advanced breast cancer. Breast. 2022; 62(1):58-62.
6. Đỗ Thị Thanh Mai, Nguyễn Tiến Quang, Phạm Văn Quân. Kết quả hoá trị trước phẫu thuật bệnh ung thư vú giai đoạn II, III bằng phác đồ TCH. Tạp chí Y học Việt Nam. 2022; 519(2).
7. Lê Hồng Quang, Đào Minh Thế. Đánh giá tình trạng di căn hạch nách và một số yếu tố liên quan trên bệnh nhân ung thư vú giai đoạn I-IIIA tại Bệnh viện K. Tạp chí Y học Việt Nam. 3/2022; 512(2):55-9.
8. Pawloski KR, Barrio AV, Gemignani ML, et al. Reconstruction in women with t4 breast cancer after neoadjuvant chemotherapy: When is it safe? Journal of the American College of Surgeons. 2021.
9. Yu AYL, Thomas SM, DiLalla GD, et al. Disease characteristics and mortality among Asian women with breast cancer. Cancer. 2022; 128(5): 1024-37.
10. Nguyễn Văn Chủ. Nghiên cứu áp dụng phân loại phân tử ung thư biểu mô tuyến vú bằng phương pháp hóa mô miễn dịch. Hà Nội: Đại học y Hà Nội; 2016.